Kinnate Biopharma Investor Presentation — June 2022

Document content

A Clinical-Stage Precision Oncology Company

Corporate Presentation

June 2022This presentation (including the accompanying oral presentation) contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical

facts contained in this presentation, including statements regarding the future financial condition, results of operations, business strategy and plans, and objectives of management for future operations

of Kinnate Biopharma Inc. ("we," "us" or "our"), as well as statements regarding industry trends, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology

such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potentially” “predict,” “should,” “will” or the negative of these terms or other similar expressions. We

have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of

operations, business strategy and financial needs.

These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: our ability to successfully complete our ongoing clinical trial and for that

trial to produce positive results, the timing of the initiation, progress and potential results of our ongoing and planned preclinical studies and clinical trials and our research programs; our ability to

advance additional product candidates into, and successfully complete, preclinical studies and clinical trials with those additional product candidates; the timing or likelihood of regulatory filings and

approvals; the negative impacts of the COVID-19 pandemic; our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our

clinical trials; the commercializing of our product candidates, if approved; our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for

commercial use, if approved; future strategic arrangements and/or collaborations and the potential benefits of such arrangements; our estimates regarding expenses, future revenue, capital

requirements and needs for financing and our ability to obtain capital; the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure

requirements; our ability to retain the continued service of our key personnel and to identify, hire and retain additional qualified professionals; the implementation of our business model, strategic plans